Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Blepharophimosis-epicanthus inversus-ptosis (BPES) due to a point mutation is a form of BPES, characterized by the classical eyelid malformation (blepharophimosis, ptosis, epicanthus inversus, and telecanthus) which may be accompanied by growth retardation and primary ovary failure.
No clinical trials have been registered for blepharophimosis-epicanthus inversus-ptosis due to a point mutation syndrome.
4 publications have been identified in PubMed for blepharophimosis-epicanthus inversus-ptosis due to a point mutation syndrome. Research spans Basic Science / Preclinical (50%), Review / Meta-Analysis (25%), and Case Report / Case Series (25%).
Colson C (2025). [PMID: 39837771](https://pubmed.ncbi.nlm.nih.gov/39837771/). *Clinical genetics*. [Review / Meta-Analysis]
Alzaben KA (2025). [PMID: 40226226](https://pubmed.ncbi.nlm.nih.gov/40226226/). *American journal of ophthalmology case reports*. [Case Report / Case Series]
Danti L (2025). [PMID: 40102860](https://pubmed.ncbi.nlm.nih.gov/40102860/). *Reproductive biology and endocrinology : RB&E*. [Basic Science / Preclinical]
Shen B (2025). [PMID: 40251640](https://pubmed.ncbi.nlm.nih.gov/40251640/). *Human genomics*. [Basic Science / Preclinical]
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 10:21 PM UTC
European rare disease database